Drug Profile
Research programme: small molecule drug discovery program - Cotinga Pharmaceuticals/Delmar Chemicals Inc.
Latest Information Update: 10 Jan 2018
Price :
$50
*
At a glance
- Originator Critical Outcome Technologies; Delmar Chemicals
- Developer Cotinga Pharmaceuticals
- Class Small molecules
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 08 Jan 2018 Critical Outcome Technologies is now called Cotinga Pharmaceuticals
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in Canada
- 12 Sep 2012 Early research in Undefined indications in Canada (unspecified route)